- Exelixis recently presented at the TD Cowen 46th Annual Health Care Conference in Boston, reinforcing its oncology focus and partnerships with Ipsen, Takeda, and Roche.
- Analyst commentary has turned more optimistic, citing Exelixis’s oncology pipeline, strengthened earnings forecasts, and valuation appeal as reasons for growing institutional interest.
- We’ll now examine how this improving analyst sentiment, supported by higher earnings forecasts, may influence Exelixis’s existing investment narrative.
Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
Exelixis Investment Narrative Recap
To own Exelixis, you need to believe its oncology franchise, partnerships, and pipeline can offset heavy reliance on CABOMETYX while managing pricing and regulatory pressures. The TD Cowen presentation and improving analyst sentiment highlight growing interest in that story, but they do not materially change the immediate catalyst around the zanzalintinib FDA review, nor the key risk that Exelixis remains highly concentrated in a single revenue driver and exposed to ongoing margin compression from discounted channels.
The most relevant recent announcement here is the FDA’s acceptance of Exelixis’s NDA for zanzalintinib plus Tecentriq in metastatic colorectal cancer, with a December 3, 2026 PDUFA date. This filing, built on STELLAR 303 overall survival data, sits at the center of the near term diversification narrative, and it is the type of development that more optimistic analysts are pointing to when they raise earnings forecasts and highlight Exelixis’s oncology pipeline as a potential offset to CABOMETYX concentration risk.
Yet while optimism is building, investors should also be aware of how dependent current margins and future cash flows still are on CABOMETYX and evolving drug pricing policy...
Read the full narrative on Exelixis (it's free!)
Exelixis’ narrative projects $3.1 billion revenue and $1.1 billion earnings by 2028.
Uncover how Exelixis' forecasts yield a $47.17 fair value, a 15% upside to its current price.
Exploring Other Perspectives
Some of the lowest analysts were assuming only about US$2.5 billion in revenue and roughly US$673.7 million in earnings by 2028, which is far more cautious than the consensus, and your view on whether rising R&D costs and tougher pricing could offset pipeline wins like zanzalintinib will likely shape how you interpret this latest news.
Explore 12 other fair value estimates on Exelixis - why the stock might be worth 14% less than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Exelixis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Exelixis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exelixis' overall financial health at a glance.
Ready For A Different Approach?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
- AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com